targeted-therapy

Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma.

Led ADMIRAL, which made gilteritinib the standard for relapsed FLT3-mutant AML.

Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs.

Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer.

Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers.

Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.

London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma.

Gustave Roussy thoracic oncologist on the IFCT board, widely published on BRAF- and EGFR-targeted therapy in lung cancer.

Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas.

Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy.

Led the imatinib trial in GIST that proved a targeted drug could melt away a solid tumour, and every GIST kinase inhibitor since.

First author of the revumenib trial that created the menin inhibitor class for acute leukaemia.

Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy.

Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer.

Led INDIGO, the trial that made vorasidenib the first targeted therapy for low-grade IDH-mutant glioma.

Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients.

Boston oncologist who led CABINET, the trial that showed cabozantinib delays progression of advanced neuroendocrine tumours after other treatments have failed.

Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills.

Duke oncologist who led MOUNTAINEER, the trial that made tucatinib plus trastuzumab the first approved HER2-directed treatment for colorectal cancer.

Spanish oncologist who helped develop trastuzumab, pertuzumab and everolimus for breast cancer, and was lead author of BOLERO-2, which established everolimus plus exemestane for hormone-receptor-positive disease.

Paris endocrine oncologist who was lead author of LIBRETTO-531, the trial that showed the selective RET inhibitor selpercatinib beats older kinase inhibitors as first treatment for advanced medullary thyroid cancer.

Korean lung cancer specialist who led CHRYSALIS, the first human study of amivantamab, whose exon 20 insertion cohort earned the drug its first approval.

Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs.

Led LIBRETTO-001 in thyroid cancer, which made selpercatinib the first RET-selective drug approved for RET-driven tumours.

Led DECISION, the trial that made sorafenib the first approved targeted drug for radioiodine-refractory thyroid cancer.

Oregon physician-scientist who showed that the KIT mutation type in a GIST predicts how well imatinib works, discovered PDGFRA mutations in the tumours without KIT mutations, and led NAVIGATOR, which established avapritinib for PDGFRA D842V disease.

New York melanoma doctor who was lead author of BRIM-3, the trial that showed vemurafenib lengthens survival in BRAF-mutant melanoma and launched targeted therapy for the disease.

Lung cancer doctor who was lead author of VISION, the trial that established tepotinib for lung cancers with MET exon 14 skipping mutations.

The leukaemia risk after chemotherapy was described in the era of mustards and etoposide, and it did not stay there. Platinum drugs carry it, PARP inhibitors raise it about two and a half times against placebo, and lenalidomide with oral melphalan raises it nearly fivefold against melphalan alone. The absolute numbers are small, but the choice of partner drug is sometimes a real decision.

Swiss dermato-oncologist who led COLUMBUS and the neoadjuvant talimogene laherparepvec studies.

Lung cancer researcher who led the pooled analysis showing that entrectinib shrinks NTRK fusion-positive tumours of many kinds, and who studied how ROS1 and NTRK cancers escape targeted drugs.

New York oncologist who was lead author of the KRYSTAL-1 colorectal report, which showed adagrasib with cetuximab shrinks KRAS G12C-mutant colorectal cancer and led to the combination's approval.

Pisa endocrinologist who led EXAM, the trial that established cabozantinib for progressive medullary thyroid cancer, and who has studied RET mutations in the disease for decades.

Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease.

Led BEACON and BREAKWATER, the trials that gave BRAF-mutant colorectal cancer its first targeted therapies.

A Shanghai lung cancer trialist who has led many Chinese PD-1 and EGFR-TKI phase 3 studies.

Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.

London gynaecological oncologist who led RAMP 201, the trial that established the avutometinib and defactinib combination for recurrent KRAS-mutant low-grade serous ovarian cancer.

Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials.